Overview
Chronic hepatitis B (CHB) is a condition for which high-genetic barrier nucleos(t)ide analogues are established treatments 1. This summary focuses on the comparative efficacy of these treatments in treatment-naïve CHB patients 1.Management
Four high-genetic barrier nucleos(t)ide analogues (NAs) are established for chronic hepatitis B (CHB): entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and besifovir dipivoxil maleate (BSV) 1.
TDF demonstrates superior virologic response compared to ETV at both 48 and 96 weeks in treatment-naïve CHB patients 1.
ETV is ranked first for 48-week biochemical response and outperforms TDF 1.Key Recommendations
For treatment-naïve chronic hepatitis B patients, tenofovir disoproxil fumarate (TDF) is recommended over entecavir (ETV) for achieving superior virologic response at 48 and 96 weeks 1. (Evidence: Strong)
Entecavir (ETV) may be considered for optimizing biochemical response at 48 weeks, as it demonstrated superiority over tenofovir disoproxil fumarate (TDF) in this outcome 1. (Evidence: Strong)References
1 Lee J, Lee A, Sung PS, Jang JW, Bae SH, Choi JY et al.. Efficacy comparison of high-genetic barrier nucleos(t)ide analogues in treatment-naïve chronic hepatitis B patients: a network meta-analysis. The Korean journal of internal medicine 2024. link